Barbara Ryan - 14 Jun 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Director
Issuer ticker: INKT
Reported as of: 14 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2023, 20:13:49 UTC
Prior SEC filing: 02 Jun 2023
Next SEC filing: 15 Jun 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Christine Klaskin, Attorney-in-Fact

Filing notes and source

Key filing fact

Barbara Ryan filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 16 Jun 2023.

Key facts

This page summarizes Barbara Ryan's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2023, 20:13.

Change

Previous filing in this sequence was filed on 02 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +37,500
Change %
Price: $0.000000
Shares after: 37,500
Date: 14 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,500
Exercise price: $2.27
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.